Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

85
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
85
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

132
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
132
Role of Neurotransmitters in Memory01:23

Role of Neurotransmitters in Memory

328
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
 Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
328
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

336
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
336

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Whole-Exome Sequencing Improves Risk Assessments of Adult Moyamoya Disease.

Journal of clinical neurology (Seoul, Korea)·2026
Same author

Preparing for the Next 20 Years.

Korean journal of neurotrauma·2026
Same author

A 20-Year Bibliometric Analysis of the <i>Korean Journal of Neurotrauma</i> Including its Transition From Domestic to International Journal.

Korean journal of neurotrauma·2026
Same author

State-of-the-Art in Robotic Rehabilitation for Spinal Cord Injury Patients: A Literature Review.

Korean journal of neurotrauma·2025
Same author

Determination of Diagnosis and Prognosis in Spinal Cord Injury Using Machine Learning.

Korean journal of neurotrauma·2025
Same author

Surgical Timing After Spinal Cord Injury: A Narrative Review of Current Evidence and Perspectives.

Korean journal of neurotrauma·2025

Related Experiment Video

Updated: May 14, 2025

Electromagnetic Controlled Closed-Head Model of Mild Traumatic Brain Injury in Mice
09:07

Electromagnetic Controlled Closed-Head Model of Mild Traumatic Brain Injury in Mice

Published on: September 28, 2022

2.0K

Effect of Choline Alfoscerate on Cognitive Dysfunction After Mild Traumatic Brain Injury: A Single-Center Prospective

Mu Seung Park1, Jin Seo Yang1, Suk-Hyung Kang1

  • 1Department of Neurosurgery, Spine Center, Chuncheon Sacred Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Chuncheon, Korea.

Korean Journal of Neurotrauma
|May 12, 2025
PubMed
Summary

Choline alfoscerate supplementation significantly improved cognitive function recovery in patients with mild traumatic brain injury. This intervention offers a promising therapeutic avenue for post-injury cognitive rehabilitation.

Keywords:
Choline alfoscerateCognitive dysfunctionMild traumatic brain injury

More Related Videos

Investigations on Alterations of Hippocampal Circuit Function Following Mild Traumatic Brain Injury
10:59

Investigations on Alterations of Hippocampal Circuit Function Following Mild Traumatic Brain Injury

Published on: November 19, 2012

15.2K
Assessing Changes in Synaptic Plasticity Using an Awake Closed-Head Injury Model of Mild Traumatic Brain Injury
09:49

Assessing Changes in Synaptic Plasticity Using an Awake Closed-Head Injury Model of Mild Traumatic Brain Injury

Published on: January 20, 2023

2.3K

Related Experiment Videos

Last Updated: May 14, 2025

Electromagnetic Controlled Closed-Head Model of Mild Traumatic Brain Injury in Mice
09:07

Electromagnetic Controlled Closed-Head Model of Mild Traumatic Brain Injury in Mice

Published on: September 28, 2022

2.0K
Investigations on Alterations of Hippocampal Circuit Function Following Mild Traumatic Brain Injury
10:59

Investigations on Alterations of Hippocampal Circuit Function Following Mild Traumatic Brain Injury

Published on: November 19, 2012

15.2K
Assessing Changes in Synaptic Plasticity Using an Awake Closed-Head Injury Model of Mild Traumatic Brain Injury
09:49

Assessing Changes in Synaptic Plasticity Using an Awake Closed-Head Injury Model of Mild Traumatic Brain Injury

Published on: January 20, 2023

2.3K

Area of Science:

  • Neuroscience
  • Clinical Medicine
  • Pharmacology

Background:

  • Mild traumatic brain injury (mTBI) can lead to persistent cognitive deficits.
  • Cognitive impairment following mTBI impacts daily functioning and quality of life.
  • Effective therapeutic strategies for mTBI cognitive recovery are crucial.

Purpose of the Study:

  • To evaluate the efficacy of choline alfoscerate in enhancing cognitive function recovery after mild traumatic brain injury.
  • To compare cognitive outcomes in mTBI patients treated with choline alfoscerate versus a placebo.

Main Methods:

  • A randomized controlled trial involving patients diagnosed with mild traumatic brain injury.
  • Cognitive function was assessed using the Korean version of the Mini-Mental State Examination (K-MMSE) at baseline and after 8 weeks of treatment.
  • Participants received either choline alfoscerate (400 mg twice daily) or a placebo for 8 weeks.

Main Results:

  • The choline alfoscerate group demonstrated a significantly greater improvement in K-MMSE scores compared to the control group (p=0.004).
  • The mean change in cognitive function over 8 weeks was 2.5±2.1 for the choline group versus 0.5±0.9 for the control group.
  • Baseline K-MMSE scores were similar between groups, indicating comparable cognitive status at the start of the study.

Conclusions:

  • Choline alfoscerate administration is associated with improved cognitive function recovery in patients with mild traumatic brain injury.
  • The findings suggest that choline alfoscerate may serve as a beneficial therapeutic agent for post-mTBI cognitive rehabilitation.
  • Further research could explore optimal dosing and long-term effects of choline alfoscerate in mTBI patients.